DNTH — DIANTHUS THERAPEUTICS INC. (Healthcare >> Biotechnology)
DNTH FAQ
What is DNTH's P/E ratio?
DIANTHUS THERAPEUTICS INC. (DNTH) currently trades at a P/E ratio of 42.69.
What is DNTH's ROE?
DIANTHUS THERAPEUTICS INC. reports a Return on Equity (ROE) of -0.94%.
What is DNTH's dividend yield?
DIANTHUS THERAPEUTICS INC. offers a dividend yield of 0.00%.
What is DNTH's Deepscope Quality Score?
Deepscope rates DNTH's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy DNTH?
Deepscope's AI Timing Score for DNTH is 56 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does DNTH belong to?
DIANTHUS THERAPEUTICS INC. is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 82.07
Price
5.62
(7.35%)
Day Change
|
|
|---|
DNTH Chất lượng tổng thể của cố phiếu Không tốt ( Chất lượng = 23) và Thời điểm mua ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
Tỷ lệ ROE tương đối thấp
Tỷ lệ ROA tương đối thấp
[-] Tốc độ tăng trưởng ROE dưới mức tiêu chí của chúng tôi.
Lịch sử ROE tương đối thấp
Tăng trưởng ROE là âm trong năm ngoái.
ROA quá thấp so với ROE
Tốc độ tăng trưởng ROA dưới mức tiêu chí của chúng tôi.
Tăng trưởng ROA dưới mức tiêu chí của chúng tôi trong năm vừa qua
Biên lợi nhuận ròng tương đối thấp.
Lịch sử Biên lợi nhuận ròng tương đối thấp.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt , Sức khỏe tài chính Không tốt , và khả năng kiếm lợi nhuận Khá , ...
| Yếu tố Chất lượng |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 67 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 82.07 |
| PBV / Sector |
3.48 / 4.91
|
| Earning Per Share | -0.22 |
| PE / Sector |
42.69 / 18.34
|
| PEG or PE/Growth / Sector |
13.05 / 0.61
|
| Average 1M Daily Value |
76.84 M
|
| Average 1W Daily Value |
136.70 M
GREAT
|
| Yếu tố Kỹ thuật |
|
42% |
| Sức khỏe tài chính |
|
37% |
| Khả năng kiếm lợi nhuận |
|
60% |
| Lợi tức cho nhà đầu tư |
|
4% |
| Chi tiết đăng ký |
| Analyze Date | 2026-06-13 11:12:57 |
| Symbol | DNTH |
| Name | DIANTHUS THERAPEUTICS INC. |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 54.67 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 4,179.23 / 9,034.83 |
| Tin tức, Dự báo ước tính |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 7 Times Square, New York, NY, United States, 10036
Phone: 929 999 4055
Website: https://dianthustx.com
Employees: 92
Sector: Healthcare >> Biotechnology
Description: Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google